Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02863718
Other study ID # CLL12
Secondary ID 2013-003211-22
Status Completed
Phase Phase 3
First received
Last updated
Start date April 30, 2014
Est. completion date July 11, 2022

Study information

Verified date November 2022
Source German CLL Study Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, multicenter, randomized, placebo-controlled, double-blind phase III study that compares the efficacy and safety of oral ibrutinib in previously untreated Binet stage A CLL patients without treatment indication according to iwCLL guidelines but risk of early disease progression. For event-free survival (EFS), an improvement from 24 months for untreated intermediate or (very) high risk CLL to 48 months for subjects treated with ibrutinib is considered clinically relevant. Ibrutinib / placebo is administered continuously orally until symptomatic disease progression, unacceptable toxicity, or voluntary treatment withdrawal, whichever occurs first.


Description:

The primary objective of the study is to demonstrate superiority of ibrutinib over placebo in prolonging EFS for subjects with treatment-naïve CLL stage A and intermediate or (very) high risk of disease progression. All subjects with intermediate, (very) high risk randomized to the experimental treatment arm will be treated up to active progressive disease with treatment indication according to iwCLL-Guidelines with the objective to demonstrate prolongation of EFS for the ibrutinib arm. EFS is defined as the time between randomization until active progressive disease with treatment indication according to the iwCLL-Guidelines with subsequent treatment for CLL or death. The secondary objectives are: - To evaluate the prolongation of overall survival of ibrutinib versus placebo - To evaluate the safety of ibrutinib versus placebo


Recruitment information / eligibility

Status Completed
Enrollment 515
Est. completion date July 11, 2022
Est. primary completion date March 7, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Previously untreated CLL - Stage Binet A without need for treatment - Age = 18 years - Life expectancy = 6 months - ECOG 0 - 2 - Signed written informed consent - Patient in the experimental arm is willing to use a highly effective contraceptive method - Male subjects in the experimental treatment arm (placebo / ibrutinib) must: - Agree to not donate semen during study drug therapy and for a period after end of study drug therapy. - For males these restrictions apply for 3 months after the last dose of study medication. - Agree not to share study medication with another person. - Be counseled about pregnancy precautions and risks of fetal exposure. - Willingness to inform the general practitioner Exclusion Criteria: - Any prior CLL specific therapy - Prior treatment with Ibrutinib or BTK inhibitors - Chronic use of steroids in excess of prednisone 20mg/day or its equivalent - Active infections requiring systemic antibiotics - An life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion could compromise the subject's safety, interfere with the absorption or metabolism of Ibrutinib capsules, or put the study outcomes at undue risk - Pregnant or lactating females - Central nervous system (CNS) involvement as documented by spinal fluid cytology or imaging. Subjects who have signs or symptoms suggestive of leukemic meningitis or a history of leukemic meningitis must have a lumbar puncture procedure performed within two weeks prior to randomization - Known second malignancy that limits survival to less than two years - Known Human Immunodeficiency Virus (HIV), active Hepatitis B Virus (HBV) and/or active Hepatitis C Virus (HCV) infection. - Any of the following laboratory abnormalities: 1. Serum aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or alanine transaminase (ALT)/serum glutamate pyruvate transaminase (SGPT) > 2.5 x upper limit of normal (ULN) 2. Serum total bilirubin > 1.5 ULN (with the exception of Gilbert's Syndrome) 3. Creatinine clearance < 30ml/min - Requires anticoagulant with warfarin or phenoprocoumon - Requires anticoagulant with oral direct Xa Inhibitors (rivaroxaban, apixaban, edoxaban) - History of stroke or intracranial hemorrhage within 6 months prior to randomization - Requires treatment with strong CYP3A4/5 Inhibitors - Participation in any clinical study for CLL or having taken any investigational therapy which would interfere with the study drug for a disease other than CLL within 28 days prior to initiating treatment. - Prisoners or subjects who are institutionalized by regulatory or court order or persons who are in dependence to the sponsor or an investigator - Patients with uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia - For males these restrictions apply for 3 months after the last dose of study medication. - Agree not to share study medication with another person. - Be counseled about pregnancy precautions and risks of fetal exposure. - Willingness to inform the general practitioner - Requires anticoagulant with warfarin or phenoprocoumon - Requires anticoagulant with oral direct Xa inhibitors (rivaroxaban, apixaban, edoxaban)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ibrutinib
Bruton's tyrosine kinase Inhibitor Ibrutinib 420mg daily
Placebo
Placebo 420mg daily

Locations

Country Name City State
Germany German CLL Study Group Cologne

Sponsors (2)

Lead Sponsor Collaborator
German CLL Study Group Janssen-Cilag Ltd.

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf O, von Tresckow J, Fink AM, Kreuzer KA, Vehling-Kaiser U, Tausch E, Müller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Wendtner CM, Fischer K, Stilgenbauer S, — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Event-free survival (EFS) EFS is defined as the time between the date of completed registration and time point of symptomatic disease progression with treatment indication, initiation of subsequent treatment for CLL or death by any cause, whichever occurs first. These will be counted as event for EFS. randomization until progression, initiation of subsequent treatment for CLL or death by any cause, whichever occurs first, assessed for at at least 60 months
Secondary Treatment-free survival The primary efficacy parameter is event-free survival (EFS) defined as the time of randomization until symptomatic disease progression with treatment indication, initiation of subsequent treatment for CLL or death by any cause, whichever occurs first time of randomization until the date of initiation of subsequent treatment for CLL or death by any cause assessed for at at least 60 months
Secondary Progression-free survival (PFS) PFS is defined by the time of randomization until symptomatic disease progression (as defined by the updated iwCLL-guidelines) or death by any cause, whichever occurs first. These will be counted as event for PFS. Patients for whom no documented event for PFS is available at the time of analysis will be censored at the time point of last follow-up information they were assessed to be event-free. the time of randomization until symptomatic disease progression (as defined by the updated iwCLL-guidelines) or death by any cause, whichever occurs first, assessed for at at least 60 months
Secondary Response rates (Overall response rate (ORR); Complete Remission (CR); Partial Remission (PR) ORR, CR- and PR- rates are defined by the proportion of patients having achieved a response (CR/CRi and nPR/PR), CR/CRi and nPR/PR as best response respectively based on the respective population. Overall response rate (ORR) achieved during treatment or within 6 months of end of treatment, complete response (CR) and partial response (PR) rates will be evaluated for at least 60 months or Progression whichever occurs first
Secondary rate of Treatment-related adverse events randomization until 28 days after the last dose of study drug
Secondary Overall survival (OS) Respectively, for watch & wait- patients (study arm I) the date of completed registration will be used. Additionally, OS will also be calculated for the time period between first diagnosis of CLL and death due to any cause. Subjects who have not yet died at the time of analysis will be censored at the time of last follow-up information they were assessed to be alive.
The exact cause of death will be recorded, with additional differentiation between CLL-related, treatment-related and other causes.
Furthermore overall survival will be analyzed using a multivariate Cox regression model adjusted for risk category, study arm, and baseline prognostic factors
date of randomization to the date of death for at least 60 months
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Completed NCT02057185 - Occupational Status and Hematological Disease
Active, not recruiting NCT04240704 - Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL Phase 1
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Active, not recruiting NCT03280160 - Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab Phase 2
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT00038025 - A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Terminated NCT02231853 - Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections Phase 1
Recruiting NCT05417165 - Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia Phase 2
Recruiting NCT04028531 - Understanding Chronic Lymphocytic Leukemia
Completed NCT00001637 - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Phase 2
Completed NCT02910583 - Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) Phase 2
Completed NCT01527045 - Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies Phase 2
Recruiting NCT04679012 - Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation Phase 2
Recruiting NCT05405309 - RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia Phase 1/Phase 2
Active, not recruiting NCT05023980 - A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Phase 3
Recruiting NCT04553692 - Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers Phase 1
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer